New Cancer Biomarker Company Formed in UK | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A new company called Oxford Cancer Biomarkers has been formed to provide oncology consulting services and new cancer biomarkers.

The company, which is headquartered in Oxford and Reading, UK, is developing new biomarkers using CancerNav, a DNA- and protein-based assay technology platform developed by Nick La Thangue, chair of cancer biology at Oxford University, and David Kerr, professor of cancer medicine at the university.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.